Press Release

May 1, 2025 – Aliri Bioanalysis, a leading provider of advanced bioanalytical and spatial multi-omics solutions for drug developers, today announced the appointment of Steve Lundy as Chief Executive Officer, and Kevin Jones as Chief Operating Officer.  This exciting transition in leadership marks a pivotal moment in Aliri’s evolution, as the company accelerates its strategic growth initiatives and further strengthens its commitment to customer excellence and service delivery.

Steve Lundy joins Aliri with over 35 years of leadership experience in the laboratory diagnostics and medical device industries at organizations including Dianon Systems, GeneOhm Sciences, Biopix, MicroPhage, and most recently Bach Diagnostics, where he served as President. Throughout his career, he has held senior leadership positions at both private and public companies, raised millions of dollars in outside capital, led the commercialization of novel diagnostic products, achieved FDA approvals, and completed successful mergers. As CEO, Steve will focus on guiding Aliri’s strategic vision, driving market expansion, and creating sustained value for customers.

Steve shares,

“I am incredibly excited to be joining this highly skilled team of industry leaders with deep expertise and a long history of scientific excellence and innovation in the bioanalytical and spatial-omics markets. Aliri Bioanalysis is well-positioned for long-term success, and I look forward to working closely with our stakeholders to accelerate growth and deliver even greater levels of value for our sponsors.”

Joining alongside is Kevin Jones, who brings over 25 years of leadership experience in operational excellence, global integration, laboratory operations, and strategic growth. Kevin has had a long and distinguished career leading large multi-disciplinary teams on a global scale, including laboratories at Covance/LabCorp and IQVIA.  Most recently, Kevin served as President of Operations at Sapient Bioanalytics, where he oversaw all aspects of daily operations, including laboratory production, R&D milestones, human resources, finance, and global compliance initiatives. As COO, Kevin will be responsible for Aliri’s operational strategy, ensuring the continued delivery of exceptional service, operational excellence, and growth across all areas of the business.

Kevin is replacing Jim Wilfahrt, who recently announced his retirement after over 30 years of service to Aliri and its legacy brand Tandem Labs.  Jim leaves a lasting impact on the people, scientific achievements, and core values of the company, and we are grateful to have his continued support as he takes on a senior advisory role.

Robin Filmer-Wilson, Partner at ARCHIMED and Chairman of Aliri Bioanalysis, shares,

“Steve and Kevin are proven leaders with strong reputations for building commercial organizations, leading company transformations, and delivering meaningful value to customers, patients, and the broader drug development community.  ARCHIMED is highly committed to supporting Aliri’s continued growth, and we have great confidence that Steve and Kevin bring the leadership, energy, and experience needed to drive the company forward.”